4月份業務強勁反彈,億仕登控股(01656.HK)前四月純利增長31.4%
格隆匯5月27日丨億仕登控股(01656.HK)公佈,儘管中國封城期漫長,集團仍取得2020年第一季度的盈利,4月各個地區的業務強勁反彈,證明了億仕登的運營準備以及亞洲工業自動化市場的新興復蘇。
於2020年第一季度,公司收入為7980萬新元,同比增長5.7%;股東應占溢利為310萬新元,同比減少26.2%。2020年截至4月30日止四個月,公司收入為1.122億新元,同比增長12.1%;股東應占溢利670萬新元,同比增長31.4%。
億仕登通過向亞洲推出創新的工業抗病毒/抗菌產品,為亞洲抵抗冠狀病毒而努力?集團對關鍵市場工業自動化業務的長期前景充滿信心
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.